Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

25.3K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.3K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
What is Genetic Engineering?00:49

What is Genetic Engineering?

74.0K
Overview
74.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harmonizing standards and resources for the medical genome.

Nature·2026
Same author

Enhancing STEMM Education Through Advanced Technologies and Collaborative Programs.

Journal of biomolecular techniques : JBT·2025
Same author

Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia.

Blood advances·2025
Same author

Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.

Transplantation and cellular therapy·2025
Same author

Conquering the gene and cell therapy viability crisis: A path paved by ASGCT.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Clearing the hurdles for CAR-T cell treatment.

Nature reviews. Immunology·2025
Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026
Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026
Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026
Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026
Same journal

Retraction.

Science (New York, N.Y.)·2026
Same journal

Making time.

Science (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

509

Cell and gene therapy accessibility.

Rayne H Rouce1, Matthew H Porteus2

  • 1Rayne H. Rouce is an associate professor at the Center for Cell and Gene Therapy, Dan L. Duncan Comprehensive Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.

Science (New York, N.Y.)
|August 1, 2024
PubMed
Summary
This summary is machine-generated.

Innovative cell and gene therapies (CGTs) offer life-changing treatments for severe diseases. However, their high cost presents a significant accessibility barrier for many patients needing these advanced medical interventions.

More Related Videos

Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications
03:52

Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications

Published on: February 9, 2024

2.5K
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

7.6K

Related Experiment Videos

Last Updated: Jun 18, 2025

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells
06:47

A GMP-Compliant Procedure for the Generation of Gene-Modified T cells

Published on: October 6, 2023

509
Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications
03:52

Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications

Published on: February 9, 2024

2.5K
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

7.6K

Area of Science:

  • Biotechnology
  • Genetics
  • Oncology
  • Hematology
  • Neurology

Background:

  • Cell and gene therapies (CGTs) represent a significant advancement in treating devastating illnesses.
  • These innovative treatments have shown promise for conditions including cancer, sickle cell disease, and neurologic disorders.

Discussion:

  • The high cost of CGTs, ranging from $300,000 to $4 million per dose, creates a substantial accessibility challenge.
  • Despite recognized long-term benefits, current pricing structures limit patient access to these potentially life-saving therapies.

Key Insights:

  • CGTs offer transformative potential for patients with severe and previously untreatable diseases.
  • The economic viability and accessibility of CGTs are critical considerations for widespread clinical adoption.

Outlook:

  • A collaborative approach involving academia, industry, investors, funders, regulators, and advocacy groups is essential.
  • Addressing the pricing and reimbursement landscape is crucial to ensure equitable access to CGT breakthroughs for all beneficiaries.